This finding reveals further crosstalk between Ras/Raf/MEK and the PI3K/Akt/mTOR signalling pathways and suggests that the Raf‐1/p70S6K pathway, especially p70S6K, could be a promising target for NSCLC treatment. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.